Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Clinical trial NCT06897579 · TERMINATED

Trial details

NCT number: NCT06897579
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Extensive Stage Small Cell Lung Cancer

Start date: 2025-04-07
Primary completion: 2026-04-15
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.